Shopping Cart
Remove All
Your shopping cart is currently empty
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | In Stock | In Stock | |
| 5 mg | $1,070 | - | In Stock | |
| 10 mg | $1,660 | - | In Stock |
| Description | Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC). |
| Synonyms | SMT-112, SMT112, AK112, AK 112 |
| Reactivity | Human |
| Verified Activity | Immobilized rhVEGF at 2 μg/mL can bind Ivonescimab. The EC50 is 0.02260 μg/mL. Immobilized huPD-1-His at 2 μg/mL can bind Ivonescimab. The EC50 is 0.07388 μg/mL. |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | VEGFA & PDCD1 |
| Molecular Weight | 201.12 kDa |
| Cas No. | 2428381-53-5 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1-LALA kappa |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.